Keystone Symposia

This meeting took place in 2013

Here are the related meetings in 2020:
Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities (J4)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Epigenetic Marks and Cancer Drugs (C8)

Organizer(s) Ali Shilatifard
March 20—25, 2013
Eldorado Hotel & Spa • Santa Fe, NM USA
Abstract Deadline: Nov 19, 2012
Late Abstract Deadline: Dec 21, 2012
Scholarship Deadline: Nov 19, 2012
Early Registration Deadline: Jan 22, 2013

Sponsored by AVEO Oncology, Celgene Corporation, Genentech, Inc. and H3 Biomedicine Inc.

Summary of Meeting:
To regulate the precise pattern of gene expression during development, eukaryotic cells have evolved to have multifaceted transcriptional machineries and chromatin states. The DNA within the eukaryotic nucleus is found in complex with histone proteins to form nucleosomes, the basic unit of chromatin. Detailed structural studies demonstrated that the N-terminal tails of each of the histones protrude outward beyond the gyres of DNA and can be posttranslationally modified. The modifications of histone tails could provide a landing pad for a diverse array of transcription factors, chromatin remodelers, and DNA-interacting proteins to regulate gene expression. Translocations and/or mutations in chromatin-modifying machineries that perturb the timing and/or pattern of gene expression can result in the pathogenesis of human diseases including cancer. Recent studies demonstrate that the misregulation of several of the histone-modifying enzymes can contribute to changes in the epigenetic state leading to disease development. Therefore, both the scientific and the pharmaceutical communities have concentrated on identifying the molecular function for many of the histone-modifying machineries and are in the process of developing small molecular inhibitors of their activities in the hope of their use for targeted therapeutics of cancer. This Keystone Symposia meeting on Epigenetic Marks and Cancer Drugs serves as a much-needed platform for bringing both the scientific and the pharmaceutical communities together to discuss recent advances in this very exciting area.

View Meeting Program


Early Career Investigator Travel Award Recipients

Elisabeth D. Martinez
University of Texas Southwestern Medical Center, USA

Keystone Symposia Future of Science Fund Scholarship Recipients

Katharin L. Shaw
Dana-Farber Cancer Institute, USA

National Institute of General Medical Sciences (NIGMS) Ancillary Training Program Scholarship Recipients

Tiffany A. Katz
University of Pittsburgh Cancer Center, USA

National Cancer Institute (NCI) Scholarship Recipients

Takamitsu Hattori
New York University School of Medicine, USA

Cigall Kadoch
Dana-Farber Cancer Institute, Harvard Medical School, USA

Mengshu Xu
University of Toronto, Canada